CA3017869C - Pyrazole aminopyrimidine derivatives as lrrk2 modulators - Google Patents
Pyrazole aminopyrimidine derivatives as lrrk2 modulators Download PDFInfo
- Publication number
- CA3017869C CA3017869C CA3017869A CA3017869A CA3017869C CA 3017869 C CA3017869 C CA 3017869C CA 3017869 A CA3017869 A CA 3017869A CA 3017869 A CA3017869 A CA 3017869A CA 3017869 C CA3017869 C CA 3017869C
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- pyrazol
- trifluoromethyl
- diamine
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41227310P | 2010-11-10 | 2010-11-10 | |
| US61/412,273 | 2010-11-10 | ||
| US201161546613P | 2011-10-13 | 2011-10-13 | |
| US61/546,613 | 2011-10-13 | ||
| CA2812669A CA2812669C (en) | 2010-11-10 | 2011-11-09 | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2812669A Division CA2812669C (en) | 2010-11-10 | 2011-11-09 | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3017869A1 CA3017869A1 (en) | 2012-05-18 |
| CA3017869C true CA3017869C (en) | 2021-07-27 |
Family
ID=44983512
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2812669A Active CA2812669C (en) | 2010-11-10 | 2011-11-09 | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
| CA3017869A Active CA3017869C (en) | 2010-11-10 | 2011-11-09 | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2812669A Active CA2812669C (en) | 2010-11-10 | 2011-11-09 | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8815882B2 (en22) |
| EP (3) | EP3590933B1 (en22) |
| JP (3) | JP5986094B2 (en22) |
| KR (1) | KR101566091B1 (en22) |
| CN (1) | CN103313978B (en22) |
| AR (1) | AR083813A1 (en22) |
| AU (1) | AU2011328139A1 (en22) |
| BR (1) | BR112013011600B1 (en22) |
| CA (2) | CA2812669C (en22) |
| CY (1) | CY1120073T1 (en22) |
| DK (2) | DK2638031T3 (en22) |
| EC (1) | ECSP13012611A (en22) |
| ES (2) | ES2746134T3 (en22) |
| HR (2) | HRP20172006T1 (en22) |
| HU (2) | HUE037844T2 (en22) |
| IL (1) | IL225234A0 (en22) |
| LT (2) | LT3124483T (en22) |
| MA (1) | MA34644B1 (en22) |
| MX (1) | MX2013005199A (en22) |
| NO (1) | NO2638031T3 (en22) |
| PH (1) | PH12013500880A1 (en22) |
| PL (2) | PL3124483T3 (en22) |
| PT (2) | PT2638031T (en22) |
| RS (2) | RS59106B1 (en22) |
| SG (1) | SG189043A1 (en22) |
| SI (2) | SI3124483T1 (en22) |
| TW (1) | TW201302733A (en22) |
| WO (1) | WO2012062783A1 (en22) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2837199A1 (en) | 2011-05-23 | 2012-11-29 | Elan Pharmaceuticals, Inc. | Cinnoline compounds as inhibitor of lrrk2 kinase activity |
| BR112014011219B1 (pt) * | 2011-11-29 | 2022-08-23 | Genentech, Inc. | Derivados de aminopirimidina, seus usos, e composição farmacêutica |
| WO2013079493A1 (en) | 2011-11-29 | 2013-06-06 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as lrrk2 modulators |
| JP6180426B2 (ja) * | 2011-11-29 | 2017-08-16 | ジェネンテック， インコーポレイテッド | パーキンソン病の処置のためのキナーゼｌｒｒｋ２モジュレーターとしての２−（フェニル又はピリド−３−イル）アミノピリミジン誘導体 |
| AR089182A1 (es) | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
| US20140228384A1 (en) * | 2011-11-29 | 2014-08-14 | Genentech, Inc. | Assays and biomarkers for lrrk2 |
| JP6148248B2 (ja) * | 2011-11-30 | 2017-06-14 | ジェネンテック， インコーポレイテッド | Ｌｒｒｋ２のポジトロン放出断層撮影（ｐｅｔ）イメージングのためのフッ素−１８及び炭素−１１標識放射性リガンド |
| CN104271569B (zh) * | 2012-05-03 | 2016-08-24 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂的吡唑氨基嘧啶衍生物 |
| RU2637948C2 (ru) * | 2012-05-03 | 2017-12-08 | Дженентек, Инк. | Производные пиразоламинопиримидина в качестве модуляторов обогащенной лейциновыми повторами киназы 2 (lrrk2) для применения при лечении болезни паркинсона |
| SG11201408044QA (en) | 2012-06-29 | 2015-01-29 | Pfizer | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS |
| WO2014060381A1 (de) | 2012-10-18 | 2014-04-24 | Bayer Cropscience Ag | Heterocyclische verbindungen als schädlingsbekämpfungsmittel |
| WO2017156493A1 (en) | 2016-03-11 | 2017-09-14 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
| WO2014134772A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| ES2665148T3 (es) | 2013-12-17 | 2018-04-24 | Merck Patent Gmbh | Derivados de N1-(3,3,3-trifluoro-2-hidroxo-2-metilpropionil)-piperidina como inhibidores de la piruvato deshidrogenasa quinasa |
| US9695171B2 (en) | 2013-12-17 | 2017-07-04 | Pfizer Inc. | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors |
| JP6483707B2 (ja) | 2013-12-20 | 2019-03-13 | シグナル ファーマシューティカルズ，エルエルシー | 置換されたジアミノピリミジル化合物、それらの組成物、及びそれらによる治療方法 |
| CA2937430A1 (en) | 2014-01-29 | 2015-08-06 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| PE20161443A1 (es) * | 2014-01-29 | 2017-01-06 | Glaxosmithkline Ip Dev Ltd | Compuestos |
| JP6538148B2 (ja) * | 2014-03-28 | 2019-07-03 | キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ | 置換されたヘテロアリール化合物および使用方法 |
| AU2015201630A1 (en) * | 2014-03-31 | 2015-10-15 | Commonwealth Scientific And Industrial Research Organisation | Diamine compounds for phosphorescent diazaborole metal complexes and electroluminescent devices |
| WO2015170600A1 (ja) * | 2014-05-08 | 2015-11-12 | 東ソー・エフテック株式会社 | ５－（トリフルオロメチル）ピリミジン誘導体及びその製造方法 |
| WO2015176010A1 (en) | 2014-05-15 | 2015-11-19 | The United States Of America, As Represented By The Secretary, Departmentof Health & Human Services | Treatment or prevention of an intestinal disease or disorder |
| JP6262079B2 (ja) * | 2014-06-02 | 2018-01-17 | 東ソー・ファインケム株式会社 | ４−（２，２，２−トリフルオロエトキシ）−５−（トリフルオロメチル）ピリミジン誘導体及びその製造方法 |
| JP6431294B2 (ja) * | 2014-06-16 | 2018-11-28 | 東ソー・ファインケム株式会社 | ５−（トリフルオロメチル）ピリミジン誘導体及びその製造法 |
| JP6649540B2 (ja) | 2014-10-14 | 2020-02-19 | ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド | 置換されたヘテロアリール化合物および使用方法 |
| MX377305B (es) | 2015-09-14 | 2025-03-07 | Pfizer | DERIVADOS DE IMIDAZO[4,5-c]QUINOLINA E IMIDAZO[4,5-c][1,5]NAFTIRIDINA NOVEDOSOS COMO INHIBIDORES DE LRRK2. |
| WO2017087905A1 (en) * | 2015-11-20 | 2017-05-26 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| AU2017242225B2 (en) | 2016-03-29 | 2021-02-18 | Merck Patent Gmbh | N1-(3,3,3-trifluoro-2-hydroxy-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase |
| EP3448850B1 (en) | 2016-04-28 | 2020-11-04 | Merck Patent GmbH | Piperidinyl derivatives |
| KR102553188B1 (ko) | 2016-06-16 | 2023-07-11 | 데날리 테라퓨틱스 인크. | 신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서 피리미딘-2-일아미노-1h-피라졸 |
| CN106588884B (zh) * | 2016-11-10 | 2019-04-09 | 浙江大学 | 2-多取代芳环-嘧啶类衍生物及制备和医药用途 |
| CN106588885B (zh) * | 2016-11-10 | 2019-03-19 | 浙江大学 | 2-取代芳环-嘧啶类衍生物及制备和应用 |
| KR101923852B1 (ko) | 2017-02-24 | 2018-11-29 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
| GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| WO2018217946A1 (en) * | 2017-05-24 | 2018-11-29 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| EP3645518B1 (en) | 2017-06-30 | 2021-05-19 | Amgen Inc. | Synthesis of omecamtiv mecarbil |
| EP3652179A1 (en) * | 2017-07-14 | 2020-05-20 | GlaxoSmithKline Intellectual Property Development Ltd | Inhibitors of leucine rich repeat kinase 2 |
| WO2019099311A1 (en) | 2017-11-19 | 2019-05-23 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| MA51222A (fr) * | 2017-11-21 | 2020-10-07 | Denali Therapeutics Inc | Polymorphes et formes solides d'un composé de pyrimidinylamino-pyrazole, et procédés de production |
| MA51339A (fr) * | 2017-12-20 | 2020-10-28 | Denali Therapeutics Inc | Procédé de préparation de composés pyrimidinyl-4-aminopyrazole |
| JP7364841B2 (ja) * | 2018-02-14 | 2023-10-19 | 智彦 大和田 | 酸ハロゲン化物による化合物の製造方法 |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| AR118641A1 (es) * | 2019-04-11 | 2021-10-20 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
| AU2020274011B2 (en) * | 2019-05-10 | 2024-02-15 | Deciphera Pharmaceuticals, Llc | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| EA202193285A1 (ru) * | 2019-05-31 | 2022-03-04 | Денали Терапьютикс Инк. | Состав с модифицированным высвобождением соединения пиримидиниламинопиразола и способы лечения |
| CN110627810B (zh) * | 2019-06-05 | 2024-05-10 | 中国医学科学院药用植物研究所 | 一种三氟甲基吡唑衍生物的制备方法 |
| EP3997081A1 (en) * | 2019-07-11 | 2022-05-18 | Escape Bio, Inc. | Indazoles and azaindazoles as lrrk2 inhibitors |
| US20230131830A1 (en) * | 2020-03-06 | 2023-04-27 | National Health Research Institutes | Pyrimidine compounds and their pharmaceutical uses |
| KR102342803B1 (ko) | 2020-03-23 | 2021-12-24 | 환인제약 주식회사 | 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물 |
| JP7671775B2 (ja) | 2020-03-23 | 2025-05-02 | ファニン ファーマシューティカル カンパニー リミテッド | 新規なピリミジン誘導体及びこれを含む神経退行性疾患及び癌の予防又は治療用組成物 |
| EP4232040A1 (en) | 2020-10-20 | 2023-08-30 | F. Hoffmann-La Roche AG | Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| US20240174679A1 (en) * | 2021-03-17 | 2024-05-30 | Merck Sharp & Dohme Llc | Heteroaroyl amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
| IL307165A (en) * | 2021-03-26 | 2023-11-01 | Sumitomo Pharma Oncology Inc | ALK-5 inhibitors and their uses |
| WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
| WO2023174946A1 (en) | 2022-03-15 | 2023-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Early and non-invasive method for assessing a subject's risk of having parkinson's disease |
| EP4525875A1 (en) * | 2022-05-20 | 2025-03-26 | Merck Sharp & Dohme LLC | Macrocycles as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
| TW202434570A (zh) | 2022-11-03 | 2024-09-01 | 美商戴納立製藥公司 | 嘧啶三唑化合物之固體及共晶體形式 |
| TW202434571A (zh) | 2022-11-22 | 2024-09-01 | 美商戴納立製藥公司 | 嘧啶胺基吡唑化合物之製備方法及中間物 |
| CN115819405A (zh) * | 2022-12-20 | 2023-03-21 | 沪渝人工智能研究院 | 嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用 |
| CN118546132A (zh) * | 2023-02-27 | 2024-08-27 | 科辉智药(深圳)新药研究中心有限公司 | 亚砜酰亚胺化合物及其作为lrrk2蛋白激酶抑制剂的应用 |
| WO2025051214A1 (zh) * | 2023-09-07 | 2025-03-13 | 上海翊石医药科技有限公司 | 一种芳杂环类化合物及其制备方法 |
Family Cites Families (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9407799A (pt) | 1993-10-12 | 1997-05-06 | Du Pont Merck Pharma | Composição de matéria método de tratamento e composição farmaceutica |
| RU2153494C2 (ru) | 1993-10-12 | 2000-07-27 | Дзе Дюпон Мерк Фармасьютикал Компани | 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция |
| BRPI9909191B8 (pt) | 1998-03-27 | 2021-07-06 | Janssen Pharmaceutica Nv | derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende |
| US6458823B1 (en) | 1998-06-08 | 2002-10-01 | Wyeth | Diaminopyrazoles |
| US6172222B1 (en) | 1998-06-08 | 2001-01-09 | American Home Products Corporation | Diaminopyrazoles |
| CA2350801C (en) | 1998-11-10 | 2008-05-20 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting pyrimidines |
| HK1045507A1 (zh) | 1999-08-12 | 2002-11-29 | Vertex Pharmaceuticals Incorporated | C-jun n-末端激酶(jnk)及其他蛋白質激酶的抑制物 |
| CN1234347C (zh) | 1999-09-24 | 2006-01-04 | 詹森药业有限公司 | 抗病毒组合物 |
| US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
| WO2001085700A2 (en) | 2000-05-08 | 2001-11-15 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting pyrimidines and triazines |
| GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002022605A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| DE60135676D1 (de) | 2000-12-05 | 2008-10-16 | Vertex Pharma | Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen |
| US7122544B2 (en) | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
| AU2002246723B2 (en) | 2000-12-21 | 2005-07-14 | Novartis Ag | Pyrimidineamines as angiogenesis modulators |
| AP1588A (en) | 2000-12-21 | 2006-03-06 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
| JP4316893B2 (ja) | 2001-05-16 | 2009-08-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｓｒｃおよび他のプロテインキナーゼのインヒビター |
| JP4291135B2 (ja) | 2001-05-29 | 2009-07-08 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Ｃｄｋ阻害性ピリミジン、それらの製造および薬剤としての使用 |
| GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| WO2002102313A2 (en) | 2001-06-19 | 2002-12-27 | Bristol-Myers Squibb Company | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| AU2002315388A1 (en) | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel phenylamino-pyrimidines and uses thereof |
| JP4510442B2 (ja) | 2001-06-26 | 2010-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | ＴＮＦ−α発現のＮ−ヘテロ環インヒビター |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| WO2003040141A1 (en) | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders |
| EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
| EP2332924A1 (de) | 2001-10-17 | 2011-06-15 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung |
| AU2002367172A1 (en) | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| US7288547B2 (en) | 2002-03-11 | 2007-10-30 | Schering Ag | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents |
| WO2003076437A1 (de) * | 2002-03-11 | 2003-09-18 | Schering Aktiengesellschaft | Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel |
| AR039540A1 (es) | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
| GB0211019D0 (en) | 2002-05-14 | 2002-06-26 | Syngenta Ltd | Novel compounds |
| GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| BR0316680A (pt) | 2002-11-28 | 2005-10-18 | Schering Ag | Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos |
| DE602004022633D1 (de) | 2003-01-30 | 2009-10-01 | Boehringer Ingelheim Pharma | 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen |
| MXPA05012362A (es) | 2003-05-21 | 2006-02-02 | Bayer Cropscience Ag | Yodopirazolilcarboxanilidas. |
| CN1823048A (zh) | 2003-07-15 | 2006-08-23 | 神经能质公司 | 作为类香草醇受体配位体的经取代的嘧啶－4－基胺类似物 |
| ES2421139T3 (es) * | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| JP2007500178A (ja) | 2003-07-30 | 2007-01-11 | サイクラセル・リミテッド | プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体 |
| EP1663242B1 (en) | 2003-08-07 | 2011-04-27 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
| DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| EP1758887A1 (en) | 2004-05-14 | 2007-03-07 | Pfizer Products Incorporated | Pyrimidine derivatives for the treatment of abnormal cell growth |
| US7754714B2 (en) | 2004-05-18 | 2010-07-13 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
| EP1598343A1 (de) | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
| JP2008505910A (ja) | 2004-07-08 | 2008-02-28 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | Ｐｋｃ−シータのインヒビターとして有用なピリミジン誘導体 |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| CA2578349A1 (en) | 2004-09-01 | 2006-03-16 | Rigel Pharmaceuticals, Inc. | Synthesis of 2,4-pyrimidinediamine compounds |
| WO2006053109A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Heteroaryl compounds |
| ES2380550T3 (es) | 2004-11-24 | 2012-05-16 | Rigel Pharmaceuticals, Inc. | Compuestos de espiro-2,4-pirimidindiamina y sus usos |
| CA2589793A1 (en) | 2004-12-17 | 2006-06-22 | Astrazeneca Ab | 4-(4-(imidazol-4-yl)pyrimidin-2-ylamino) benzamides as cdk inhibitors |
| US8211929B2 (en) | 2004-12-30 | 2012-07-03 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| DE102005008310A1 (de) | 2005-02-17 | 2006-08-24 | Schering Ag | Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle |
| EP1705177A1 (en) | 2005-03-23 | 2006-09-27 | Schering Aktiengesellschaft | N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents |
| US20080194606A1 (en) | 2005-05-05 | 2008-08-14 | Astrazeneca | Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer |
| NZ563454A (en) | 2005-06-08 | 2011-03-31 | Rigel Pharmaceuticals Inc | 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway |
| US7576053B2 (en) | 2005-06-13 | 2009-08-18 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
| WO2006138304A2 (en) | 2005-06-14 | 2006-12-28 | Taigen Biotechnology | Pyrimidine compounds |
| US20070032514A1 (en) | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| WO2007023382A2 (en) | 2005-08-25 | 2007-03-01 | Pfizer Inc. | Pyrimidine amino pyrazole compounds, potent kinase inhibitors |
| EA200800755A1 (ru) | 2005-09-07 | 2008-10-30 | Лаборатуар Сероно С.А. | Ikk ингибиторы, предназначенные для лечения эндометриоза |
| US20090149467A1 (en) * | 2005-09-15 | 2009-06-11 | Merck & Co., Inc. | Tyrosine Kinase Inhibitors |
| DE102005048072A1 (de) | 2005-09-24 | 2007-04-05 | Bayer Cropscience Ag | Thiazole als Fungizide |
| WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| PE20080068A1 (es) | 2006-05-15 | 2008-03-17 | Boehringer Ingelheim Int | Compuestos derivados de pirimidina como inhibidores de la quinasa aurora |
| DE102006027156A1 (de) | 2006-06-08 | 2007-12-13 | Bayer Schering Pharma Ag | Sulfimide als Proteinkinaseinhibitoren |
| CA2655315A1 (en) | 2006-06-15 | 2007-12-21 | Boehringer Ingelheim International Gmbh | 2-anilino-4-aminoalkyleneaminopyrimidines |
| US20080131937A1 (en) | 2006-06-22 | 2008-06-05 | Applera Corporation | Conversion of Target Specific Amplification to Universal Sequencing |
| JP2009545598A (ja) | 2006-08-01 | 2009-12-24 | プリーシス・ファーマシューティカルズ・インコーポレイテッド | Ｐ３８キナーゼ阻害剤 |
| DE102006041382A1 (de) | 2006-08-29 | 2008-03-20 | Bayer Schering Pharma Ag | Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren |
| US20080194575A1 (en) | 2006-10-04 | 2008-08-14 | Naiara Beraza | Treatment for non-alcoholic-steatohepatitis |
| US20100069316A1 (en) | 2006-11-27 | 2010-03-18 | Ares Trading S.A. | Treatment for multiple myeloma |
| BRPI0720264B1 (pt) | 2006-12-08 | 2022-03-03 | Novartis Ag | Compostos e composições como inibidores de proteína cinase |
| GB0625196D0 (en) | 2006-12-18 | 2007-01-24 | 7Tm Pharma As | Modulators of cannabinoid receptor |
| WO2008079719A1 (en) | 2006-12-19 | 2008-07-03 | Genentech, Inc. | Pyrimidine kinase inhibitors |
| EP1939185A1 (de) | 2006-12-20 | 2008-07-02 | Bayer Schering Pharma Aktiengesellschaft | Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs |
| EP2109605B1 (en) | 2006-12-22 | 2013-02-20 | Boehringer Ingelheim International GmbH | 2- [(phenylamino) -pyrimidin-4ylamin0] -cyclopentane carboxamide derivatives and related compounds as inhibitors of kinases of the cell cycle for the treatment of cancer |
| WO2008099210A2 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| DE102007010801A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Cropscience Ag | Diaminopyrimidine als Fungizide |
| UY31048A1 (es) | 2007-04-25 | 2008-11-28 | Astrazeneca Ab | Nuevos compuestos de pirimidina y usos de los mismos |
| BRPI0809896A2 (pt) | 2007-06-08 | 2014-10-07 | Bayer Cropscience Sa | Composto, composição fungicida e método para controle de fungos fitopatogênicos de culturas |
| AU2008275918B2 (en) | 2007-07-17 | 2014-01-30 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as PKC inhibitors |
| EP2205603B1 (en) | 2007-09-28 | 2014-01-15 | Cyclacel Limited | Pyrimidine derivatives as protein kinase inhibitors |
| JP5548130B2 (ja) | 2007-10-09 | 2014-07-16 | ダウ アグロサイエンシィズ エルエルシー | 殺虫性ピリミジニルアリールヒドラゾン |
| MY152948A (en) | 2007-11-16 | 2014-12-15 | Incyte Corp | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
| US8461147B2 (en) | 2007-12-03 | 2013-06-11 | Boehringer Ingelheim International Gmbh | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
| ES2374480T3 (es) | 2007-12-07 | 2012-02-17 | Novartis Ag | Derivados pirazol y uso de los mismos como inhibidores de quinasas dependientes de ciclina. |
| MX2010008926A (es) | 2008-02-15 | 2011-02-23 | Rigel Pharmaceuticals Inc | Compuestos de pirimidin-2-amina y su uso como inhibidores de jak cinasas. |
| CL2009000600A1 (es) | 2008-03-20 | 2010-05-07 | Bayer Cropscience Ag | Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas. |
| WO2009122180A1 (en) | 2008-04-02 | 2009-10-08 | Medical Research Council | Pyrimidine derivatives capable of inhibiting one or more kinases |
| WO2009127642A2 (en) * | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
| KR101956261B1 (ko) | 2008-05-21 | 2019-03-08 | 어리어드 파마슈티칼스, 인코포레이티드 | 키나아제 억제제로서 포스포러스 유도체 |
| US8445505B2 (en) | 2008-06-25 | 2013-05-21 | Irm Llc | Pyrimidine derivatives as kinase inhibitors |
| EP2303824B1 (en) | 2008-06-25 | 2015-03-25 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| UY31929A (es) | 2008-06-25 | 2010-01-05 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| PE20110403A1 (es) | 2008-07-31 | 2011-07-04 | Genentech Inc | Compuestos biciclicos fusionados de pirimidina en el tratamiento del cancer |
| WO2010024430A1 (ja) | 2008-09-01 | 2010-03-04 | アステラス製薬株式会社 | 2,4-ジアミノピリミジン化合物 |
| WO2010028179A1 (en) | 2008-09-03 | 2010-03-11 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds as gata modulators |
| EP2161259A1 (de) | 2008-09-03 | 2010-03-10 | Bayer CropScience AG | 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide |
| CN102143688A (zh) | 2008-09-03 | 2011-08-03 | 拜尔农作物科学股份公司 | 4-烷基-取代的二氨基嘧啶类化合物 |
| EP2331533A1 (de) | 2008-09-03 | 2011-06-15 | Bayer CropScience AG | Heterozyklisch substituierte anilinopyrimidine als fungizide |
| EA201100436A1 (ru) | 2008-09-03 | 2011-10-31 | Байер Кропсайенс Аг | Гетероциклически замещенные анилинопиримидины в качестве фунгицидов |
| WO2010038081A2 (en) | 2008-10-03 | 2010-04-08 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
| UY32240A (es) | 2008-11-14 | 2010-06-30 | Boeringer Ingelheim Kg | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. |
| GB0821307D0 (en) | 2008-11-21 | 2008-12-31 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| CA2748181C (en) | 2009-01-06 | 2019-07-16 | Nathanael S. Gray | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| US20110071158A1 (en) | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
| RU2011143740A (ru) * | 2009-03-30 | 2013-05-10 | Астеллас Фарма Инк. | Соединение пиримидина |
| WO2010118986A1 (en) | 2009-04-14 | 2010-10-21 | Cellzome Limited | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
| EP2440559B1 (en) | 2009-05-05 | 2018-01-10 | Dana-Farber Cancer Institute, Inc. | Egfr inhibitors and methods of treating disorders |
| TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| WO2010144468A1 (en) * | 2009-06-10 | 2010-12-16 | Abbott Laboratories | 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors |
| US20120142667A1 (en) | 2009-06-10 | 2012-06-07 | Nigel Ramsden | Pyrimidine derivatives as zap-70 inhibitors |
| AR077033A1 (es) | 2009-06-11 | 2011-07-27 | Hoffmann La Roche | Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas |
| EP2443095A1 (en) | 2009-06-18 | 2012-04-25 | Cellzome Limited | Sulfonamides and sulfamides as zap-70 inhibitors |
| WO2010146133A1 (en) | 2009-06-18 | 2010-12-23 | Cellzome Limited | Heterocyclylaminopyrimidines as kinase inhibitors |
| MX339811B (es) | 2009-09-16 | 2016-06-08 | Celgene Avilomics Res Inc * | Conjugados e inhibidores de cinasa de proteina. |
| CA2775753A1 (en) | 2009-09-29 | 2011-04-07 | Paula Louise Nichols | Lrrk2 kinase inhibitors |
| CN102811619B (zh) | 2009-11-13 | 2015-04-22 | 金纳斯克公司 | 激酶抑制剂 |
| WO2011090762A1 (en) | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Heterodimer binding proteins and uses thereof |
| US8470820B2 (en) | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
| SG185641A1 (en) * | 2010-06-04 | 2012-12-28 | Hoffmann La Roche | Aminopyrimidine derivatives as lrrk2 modulators |
| WO2013079493A1 (en) * | 2011-11-29 | 2013-06-06 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as lrrk2 modulators |
| JP6180426B2 (ja) * | 2011-11-29 | 2017-08-16 | ジェネンテック， インコーポレイテッド | パーキンソン病の処置のためのキナーゼｌｒｒｋ２モジュレーターとしての２−（フェニル又はピリド−３−イル）アミノピリミジン誘導体 |
| AR089182A1 (es) * | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
| BR112014011219B1 (pt) * | 2011-11-29 | 2022-08-23 | Genentech, Inc. | Derivados de aminopirimidina, seus usos, e composição farmacêutica |
| JP6148248B2 (ja) * | 2011-11-30 | 2017-06-14 | ジェネンテック， インコーポレイテッド | Ｌｒｒｋ２のポジトロン放出断層撮影（ｐｅｔ）イメージングのためのフッ素−１８及び炭素−１１標識放射性リガンド |
-
2011
- 2011-11-09 HR HRP20172006TT patent/HRP20172006T1/hr unknown
- 2011-11-09 ES ES16180927T patent/ES2746134T3/es active Active
- 2011-11-09 SG SG2013021100A patent/SG189043A1/en unknown
- 2011-11-09 EP EP19184916.5A patent/EP3590933B1/en active Active
- 2011-11-09 DK DK11782588.5T patent/DK2638031T3/en active
- 2011-11-09 LT LTEP16180927.2T patent/LT3124483T/lt unknown
- 2011-11-09 DK DK16180927.2T patent/DK3124483T3/da active
- 2011-11-09 HU HUE11782588A patent/HUE037844T2/hu unknown
- 2011-11-09 US US13/292,668 patent/US8815882B2/en active Active
- 2011-11-09 PL PL16180927T patent/PL3124483T3/pl unknown
- 2011-11-09 KR KR1020137014605A patent/KR101566091B1/ko active Active
- 2011-11-09 CA CA2812669A patent/CA2812669C/en active Active
- 2011-11-09 AR ARP110104181A patent/AR083813A1/es not_active Application Discontinuation
- 2011-11-09 BR BR112013011600-5A patent/BR112013011600B1/pt active IP Right Grant
- 2011-11-09 EP EP16180927.2A patent/EP3124483B1/en active Active
- 2011-11-09 CN CN201180053793.8A patent/CN103313978B/zh active Active
- 2011-11-09 SI SI201131772T patent/SI3124483T1/sl unknown
- 2011-11-09 WO PCT/EP2011/069696 patent/WO2012062783A1/en active Application Filing
- 2011-11-09 PH PH1/2013/500880A patent/PH12013500880A1/en unknown
- 2011-11-09 PT PT117825885T patent/PT2638031T/pt unknown
- 2011-11-09 NO NO11782588A patent/NO2638031T3/no unknown
- 2011-11-09 RS RS20191033A patent/RS59106B1/sr unknown
- 2011-11-09 HU HUE16180927A patent/HUE046617T2/hu unknown
- 2011-11-09 ES ES11782588.5T patent/ES2653967T3/es active Active
- 2011-11-09 PL PL11782588T patent/PL2638031T3/pl unknown
- 2011-11-09 PT PT161809272T patent/PT3124483T/pt unknown
- 2011-11-09 TW TW100140970A patent/TW201302733A/zh unknown
- 2011-11-09 JP JP2013538172A patent/JP5986094B2/ja active Active
- 2011-11-09 CA CA3017869A patent/CA3017869C/en active Active
- 2011-11-09 SI SI201131377T patent/SI2638031T1/en unknown
- 2011-11-09 EP EP11782588.5A patent/EP2638031B9/en active Active
- 2011-11-09 MX MX2013005199A patent/MX2013005199A/es active IP Right Grant
- 2011-11-09 LT LTEP11782588.5T patent/LT2638031T/lt unknown
- 2011-11-09 RS RS20171211A patent/RS56583B1/sr unknown
- 2011-11-09 AU AU2011328139A patent/AU2011328139A1/en not_active Abandoned
-
2013
- 2013-03-14 IL IL225234A patent/IL225234A0/en unknown
- 2013-05-03 MA MA35869A patent/MA34644B1/fr unknown
- 2013-05-08 EC ECSP13012611 patent/ECSP13012611A/es unknown
-
2016
- 2016-08-04 JP JP2016153608A patent/JP6298115B2/ja active Active
-
2017
- 2017-12-27 CY CY20171101349T patent/CY1120073T1/el unknown
-
2018
- 2018-02-22 JP JP2018029462A patent/JP6524284B2/ja active Active
-
2019
- 2019-10-02 HR HRP20191781TT patent/HRP20191781T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3017869C (en) | Pyrazole aminopyrimidine derivatives as lrrk2 modulators | |
| CA2870049C (en) | Pyrazole aminopyrimidine derivatives as lrrk2 modulators | |
| CA2850705C (en) | 2-(phenyl or pyrid-3-yl)aminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease | |
| HK1235767A1 (en) | Pyrazole aminopyrimidine derivatives as lrrk2 modulators | |
| HK40018794A (en) | Pyrazole aminopyrimidine derivatives as lrrk2 modulators | |
| HK40018794B (en) | Pyrazole aminopyrimidine derivatives as lrrk2 modulators | |
| AU2013203083A1 (en) | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | |
| HK1235767B (en) | Pyrazole aminopyrimidine derivatives as lrrk2 modulators | |
| HK1187605B (en) | Pyrazole aminopyrimidine derivatives as lrrk2 modulators | |
| HK1200820B (en) | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180919 |